Exhibit 99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G initially filed on August 31, 2017, as amended on February 7, 2020 and May 22, 2024 (the “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Coherus BioSciences, Inc. is, and any further amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an exhibit to the Schedule 13G and each such amendment.

Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 22nd day of May, 2024.

Dated: May 22, 2024	TEMASEK HOLDINGS (PRIVATE) LIMITED
	By:	/s/ Jason Norman Lee
		Name	:	Jason Norman Lee
		Title	:	Authorized Signatory
Dated: May 22, 2024	FULLERTON MANAGEMENT PTE LTD
	By:	/s/ Gregory Tan
		Name	:	Gregory Tan
		Title	:	Director
Dated: May 22, 2024	TEMASEK LIFE SCIENCES PRIVATE LIMITED
	By:	/s/ Lim Siew Lee Sherlyn
		Name	:	Lim Siew Lee Sherlyn
		Title	:	Director
Dated: May 22, 2024	V-SCIENCES INVESTMENTS PTE LTD
	By:	/s/ Khoo Ken Hui
		Name	:	Khoo Ken Hui
		Title	:	Director